| |
|
|
|
Xtalks, online
2023 -5-11
The game has changed in biotech. Continued macroeconomic uncertainty has far reaching implications for the biopharma ecosystem. Access to capital remains low across the industry, and a successful deal with large pharma has become less likely for many. Companies who earlier would have been sellers, may now be progressing development through registrational studies — or all the way through to market. Stated another way, biotechs can no longer operate toward the single goal of being acquired by, or of licensing their assets to, large pharma — accordingly, players may need to develop products further than in the past, and therefore strategic pathway optionality needs to be weaved into and maintained throughout product and corporate development. With these new challenges come multifold new opportunities for value creation.
Syneos Health and Treehill Partners are at the center of this landscape, devising concerted product, corporate and business development strategies with customers to navigate the evolving market.
In this webinar, the featured speakers will discuss strategic and operational implications for the biotech C-suite and share perspectives on how companies can succeed in an increasingly competitive environment.
The speakers also look to address some pressing questions such as:
How far to go as a biotech (and in what circumstances)
Value focused clinical development
Strategic capital allocation
How patients may benefit in the long run from the evolution and increasing sophistication of the biotech ecosystem
Register now to learn about new opportunities for biotechs for value creation.
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Lee Taurman, Global Head of Syneos One, Syneos Health Keith Ruark, SVP Strategic Business Development, Syneos Health Ali Pashazadeh, Founder, Treehill Partners
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2023 -5-11
|
|
|
|
|
|
|
|
Registration:
|
|
Free registration
|
|
|
E-mail:
|
|
ajuurinen@xtalks.com
|
|
|
|
|
|
|
|
|